Europe's medicine shortages turn structural in 2026 as cancer, TB, epilepsy and insulin supplies falter

Shortages of critical medicines in Europe are hardening into a permanent feature of the market in 2026, with treatments for cancer, tuberculosis, epilepsy and diabetes moving into what Greek outlet sbctv.gr describes as the danger zone. European authorities no longer treat the problem as a series of isolated incidents but as a continuing failure in production and distribution, and medicine supply is now handled as a question of strategic security in the same way as energy or defence.

The scale of the problem

In 2025 the European monitoring mechanism received 70 notifications of critical shortages, while the dedicated task force of the European Medicines Agency (EMA) met 31 times on this issue alone, according to sbctv.gr. Early in 2026 the EMA revised the European Union list of critical medicines, covering products whose continuous availability is considered essential for health systems to function without putting patients at risk. That list is now used as a prevention tool rather than as a record of problems already under way.

The products under scrutiny in 2026 span several therapeutic areas:

• ifosfamide and cyclophosphamide, two core oncology medicines;
• anti-tuberculosis treatments;
• the anthelmintic albendazole;
• certain insulin preparations;
• the antibiotic aztreonam;
• immunoglobulins and other critical products.

One plant, many countries

In March 2026 the EMA announced that shortages of ifosfamide and cyclophosphamide were affecting EU member states and European Economic Area countries, and were expected to continue for the rest of the year. The cause was serious production problems at a facility of the main European supplier, which reduced available manufacturing capacity and left supply insufficient to cover demand.

In June and July 2026 authorities were still tracking shortages of antibiotics, anti-tuberculosis medicines, oncology products, immunoglobulins, insulins and epilepsy treatments. For the antiepileptic Topamax, the EMA estimates that the shortage of tablets, caused by manufacturing problems, will continue until the end of 2026 in several countries.

The issue is not only how many packs sit on pharmacy shelves but how resilient the production and distribution chain itself is. A breakdown at one plant, a difficulty in sourcing an active substance, or a company decision to withdraw a product can hit many countries at the same time, especially where few alternative manufacturers exist.

From crisis response to supply resilience

European authorities acknowledge that the causes are global and complex. Their stated priority has shifted towards strengthening the reliability and resilience of supply chains rather than managing each shortage only once it breaks out. On the same reading, Europe is not facing a single uniform medicine shortage but a persistent vulnerability of the market that shows up differently in each country.

European guidance asks doctors and pharmacists to give priority to patients already receiving a specific treatment, so that therapy is not interrupted abruptly. Changes are made only where absolutely necessary and medically appropriate, and may involve a different product, a different dosage form such as a solution instead of a tablet, or a switch to an alternative therapy where that is clinically safe.

Greece as a test case

According to the assessment published by sbctv.gr, Greece imports a large share of its medicines and domestic production is limited in certain categories, so European vulnerability translates directly into risk for daily clinical practice in the national health system. The outlet calls for a national plan covering critical medicines, including oncology products, antibiotics, insulins and antiepileptics, for domestic production to be strengthened where feasible, and for continuous dialogue between the national medicines agency, the pharmaceutical industry, pharmacists and medical associations so that shortages are anticipated and managed before they reach the patient.

Practical advice for patients follows the same logic: obtain chronic medication in good time without hoarding excessive quantities, inform the treating physician immediately if a shortage is encountered, and avoid buying medicines through unregulated online channels, where counterfeit or dangerous products may circulate. Patients are advised never to change a medicine or dosage on their own because a single pharmacy has run out.